Podcasts about horizon therapeutics

Episode #359 – A Look Back on 2024  Hi I'm David Hirsch, founder of the 21st Century Dads Foundation and Special Fathers Network as well as host of the Special Fathers Network Dad To Dad Podcast.   Happy New Year and welcome to the first episode of 2025.   Tom Couch, the editor and producer of the SFN Dad To Dad Podcast, and I, thought we would do something special and provide a Look Back on 2024.   In total we produced 72 episodes, 52 were weekly episodes airing on Fridays and for 20 weeks from May through September we produced a series of short episodes with SFN Mentor Fathers who are also involved with the SFN Mastermind Group program.  We called them SFN Mastermind Group Monday Podcasts.    While we'd love to include a snippet from all 70+ episodes, to keep it more concise we decided to provide some highlights.   We hope you enjoy listening to this Look Back on 2024 Episode as much as we did producing it.   18 of the 2024 guests are authors.   Nine of the interviews included international guests, from the following seven countries: Australia, Canada, Cayman Islands, Cuba, Iceland, Israel and the UK.  Four of the guests are women.  Three interviews were with dads who lost a child including one who was an Israeli hostage killed by Hamas terrorists.  Two interviews included military veterans: a former U.S. Navy Seal and a U.S. Air Force Vietnam-era combat pilot.  And one of the guests is a Native American.   The episodes also spanned a very broad range of disabilities including; Autism, Down Syndrome, Cerebral Palsy, Rare Disease, Dwarfism as well as those who are blind, deaf and missing a limb(s).    Here is a brief month by month recap with a clip from a select number of episodes.   In January, we aired four episodes including a dad from the UK and one from the Cayman Islands as well as with Jonathan Eig, father to three, including a son whose parents passed away at an early age.  Jon is also the best-selling author of biographies on: Muhammad Ali, Lou Gehrig, and MLK.   In February, we aired four episodes including one with Dave Jereb of Sydney, Australia, a Physical Therapist, co-founder of Move About Therapies and author of the book: Challenging The Story. We also did a two-episode story with filmmaker Bob Manganelli, whose 23 year old deaf son, very tragically committed suicide, while at Gallaudet University back in 2014.  In March, we produced five episodes including a two-episode interview with Keith Harris of Albuquerque, NM who is a retired business owner and father of four, including son Tim who has Down Syndrome.   He and Tim owned and operated the restaurant Tim's Place for five years.  Tim also went on to author The Book of Hugs, a children's book.  In April, we aired four episodes including one with Jonathan Bennett of Ontario Canada, who is an executive leadership coach, author and father of two, including one with Autism who is also non-binary.  In May, we did six episodes including one with Dr. Greg Pursley of Jackson, MO who is a chiropractor, owner of PC Medical Centers, an author and father of two, including a son who has Dwarfism.   We also interviewed John Borling of Rockford, IL who is a retired Major General in the U.S. Air Force.  John was a combat pilot in Vietnam who flew 97 missions before being shot down and held hostage for six years, eight months at the Infamous Hanoi Hilton.  And we interviewed Jon Ghahate a Pueblo Indian from Placitas, NM who is a Vietnam-er veteran and father of three, including a daughter who is sight impaired.  In June, we produced eight episodes including four SFN Mastermind Group Monday interviews with testimonials about their mastermind group experiences.  One was with John Shouse of Franklin, TN an industrial control engineer and father of three including twin boys, one of which, Evan, is Autistic.   John and his wife, Janet, have been leaders in the disability community throughout TN and John has been involved with the Tuesday night Mastermind group for nearly three years.   We also interviewed Paul Briggs of Falling Waters, WV, who is the father of 38.  No this was not a typographical error or some misstatement.  Paul and his wife, Jeanne, have six biological kids and 32 adopted children including: 13 from Ghana, 10 from Ukraine, six from Russia, two from Bulgaria and one from Mexico.   In July, we did nine episodes including five Mastermind Group Monday interviews.  We also interviewed Kelley Coleman of Los Angeles, CA, a mother of two, a disability advocate, and author of Everything No One Tells You About Parenting a Disabled Child: Your Guide to the Essential Systems, Services, and Supports.   We also interviewed Sam Farmer of North Easton, MA who is the father of a son with Autism and later in life was also diagnosed with Asperger's.  Sam is also the author of A Long Walk Down A Winding Road and has become one of the more well recognized self-advocates in the Autism community.  We also Al Malavolti of Rockford, IL in a two-part interview.  Al is a retired aerospace executive and he and his wife, Rosemary, have 22 children including four biologic kids and 17 adopted kids, and one they parented.   In August, we aired nine episodes including four Mastermind Group Monday episodes, including one with Tom Costello of Frankfort, IL who is the father of twin 21-year-old boys who are Autistic.  Tom and his wife Irene created the Twin Autism Foundation and have been outspoken advocates for those diagnosed with ASD.    We also interviewed Alvin Green of Chicago who is a retired Chef.  Alvin and his wife, Angela Ferguson, have two boys including Aiden who is Autistic.  To provide Aiden with some career skills and to support himself, Alvin founded Al's Cookie Mixx, a premium online cookie business that employs individuals who have intellectual disabilities.  In September, we produced nine episodes including five Mastermind Group Monday episodes and one with Agust Kristmanns of Reykjavik, Iceland who is the father of three including son, Ingi, who has 2Q37 Deletion syndrome, a rare chromosome condition that affects his development.  We also interviewed Jonathan Polin who is an Israeli-American.  Jonathan and his wife, Rachel Goldberg-Polin, became some of the most outspoken advocates speaking out about the urgency behind releasing the Israelis being held hostage by Hamas.  They met with the Pope at the Vatican and President Biden at the White House.  They spoke at the United Nations in Geneva and at the Democratic National Convention in Chicago.  I interviewed Jonathan on day 328 of their son Hersh's captivity and very sadly, just days later we learned about Hamas murdering six of the hostages including Hersh.   In October, we aired five episodes including one with Dr. Ruslan Vasyutin who is a single Ukrainian father to 12 year old daughter Alicia, who has Cerebral Palsy and unable to walk or talk.  They are currently living in Solihull, England after fleeing Kiev in February 2022 after the Russia invasion of Ukraine.    We also interviewed Andrew Bustamante of Colorado Springs, CO who is the father of two young children.  Andrew and his wife, Jihi, are both x-CIA undercover intelligence officers and hosts of the EverydaySpy Podcast.  It was a fascinating conversation about utilizing CIA tactics to overcome adversity.   In November, we produced five episodes including one with fellow podcaster daughter-father team: Reena Friedman Watts and her father Wayne, who produce the Better Call Daddy Podcast.  We also interviewed Todd Evans of Brentwood, TN who is an entrepreneur.  He and his wife Kristin have two children with disability and are the co-authors of How To Build A Thriving Marriage As You Care For Children With Disabilities.  And in December we did four episodes including one with former U.S. Navy Seal Phillip Koontz who is a business owner, leadership coach and speaker, father of five including an Autistic son and author of the book: The Truth Behind My Trident, which provides a fascinating look behind the curtain of the life as a U.S. Navy Seal.  We also interviewed Emma Livingstone of London, England who is the mother of three typical kids, who herself has Cerebral Palsy and is founder and CEO of UP - The Adult Movement For Adults With Cerebral Palsy.   All in all 2024 was an extraordinary year for the 21st Century Dads Foundation and Special Fathers Network.    I want to offer my heartfelt thanks to:  Tom Couch, our SFN Dad To Dad Podcast editor and producer and my partner in crime,            To Our primary sponsor Horizon Therapeutics for the ongoing and generous support,           To all those who agreed to do interviews this past year, some of which were included here, andPerhaps most importantly of all, YOU our valued listeners for tuning in week after week and sharing the episodes with family and friends.   For more information, please go to the show notes or visit: www.21stCenturyDads.org.  Thank you again and best wishes to you and your family for a safe and healthy new year.Special Fathers Network - SFN is a dad to dad mentoring program for fathers raising children with special needs. Many of the 800+ SFN Mentor Fathers, who are raising kids with special needs, have said: "I wish there

Carol O'Kelly is regarded as one of the leading proponents of Personal Branding, Communications, and Positioning Strategy for high-level C-suite and Owner/Managers, having worked with key teams in companies such as EY, KPMG, Horizon Therapeutics, BoI Corporate Banking, and The Executive Institute. She's the Founder & CEO of Redstorm Communications Ltd, which she established as a Strategic Marketing & Communications Agency in 2003 and still works with many of the same clients she had when she opened the doors - a fact she's immensely proud of. Hear why your personal brand matters, how to get started developing your personal brand, why confidence can be learned & nerves are a good thing, how to speak authentically on LinkedIn & other social media platforms, and how to celebrate what makes you remarkable. Connect with Shirley at ShirleyKavanagh.com and on LinkedIn, and Carol at Redstorm.ie and on LinkedIn

This week, we revisit our interview with John Milad. John has 25 years of experience as a start-up executive, venture investor, and banker specializing in healthcare innovation across the UK, Europe, and the US. He had 10 years of life sciences venture experience at a family office, Atlas Venture, NBGI Venture and Downing. Notable exits include Symetis, ACT/EPIX, BoneSupport and Medcast/WebMD. John is a Co-founder of Quanta Dialysis Technologies, which I led as CEO for 8 years. Notable outcomes include creating an award-winning, disruptive portable dialysis system; raising nearly $400m in funding; commercially launching in UK and US; and establishing trans-Atlantic commercial operations. For another 2 years, he served as an executive at Nitec Pharma, which was ultimately sold to Horizon Therapeutics. John has held multiple board positions across the sector. He has been an advisor to NIIR/I4i programme, mentor at the Enterprise Hub of the Royal Academy of Engineering.  He has been recognized in the Sunday Times Maserati List of the UK's Top 100 “Game Changing Innovators and Entrepreneurs”; Winner of the 2022 MacRobert Award from the Royal Academy of Engineering for outstanding engineering innovation.

English Version - In April 2023, our host David Hirsch traveled to Cuba with Joni and Friends, as one of 12 U.S. volunteers participating in a Wheels For The World Program, to fit and distribute 200+ wheelchairs to youth and adults, who might not otherwise experience mobility.   This week's guest is Leonardo Cespedes of Bayamo, Cuba, a Baptist Preacher and father of two including a son with intellectual and physical disabilities.  Leonardo and his wife, Mairelis, have been married for 26 years and are the proud parents of two; daughter Reveca (23) who is a teacher, and son Marko (20) who has undiagnosed intellectual disabilities, suffers from seizures and is hard of hearing.   Marko was one of the recipients of a wheelchair. During his visit, David spoke with and recorded interviews with two Cubans connected to the disability community in Cuba.  Special thanks to Dairy Hernandez, the young Cuban woman that served as one of David's translators during the week and for her help translating today's episode in English and Spanish.  That's all on this episode of the SFN Dad to Dad Podcast.  Show Notes - WhatsApp - 53 58 01 426 627 Email – leobayamo@nauta.cuJoni & Friends -  https://joniandfriends.org/ACLIFIM (Asociación Cubana de Personas con Discapacidad Físico - Motora -  https://www.aclifim.cu/Special Fathers Network - SFN is a dad to dad mentoring program for fathers raising children with special needs. Many of the 700+ SFN Mentor Fathers, who are raising kids with special needs, have said: "I wish there was something like this when we first received our child's diagnosis. I felt so isolated.  There was no one within my family, at work, at church or within my friend group who understood or could relate to what I was going through."SFN Mentor Fathers share their experiences with younger dads closer to the beginning of their journey raising a child with the same or similar special needs. The SFN Mentor Fathers do NOT offer legal or medical advice, that is what lawyers and doctors do. They simply share their experiences and how they have made the most of challenging situations.Check out the 21CD YouTube Channel with dozens of videos on topics relevant to dads raising children with special needs - https://www.youtube.com/channel/UCzDFCvQimWNEb158ll6Q4cA/videosPlease support the SFN. Click here to donate: https://21stcenturydads.org/donate/Special Fathers Network: https://21stcenturydads.org/SFN Dads Mastermind Group - https://21stcenturydads.org/sfn-mastermind-group/Find out about Horizon Therapeutics – Science and Compassion Working Together To Transform Lives. https://www.horizontherapeutics.com/Versión en Español - En abril de 2023, nuestro anfitrión David Hirsch viajó a Cuba con Joni y sus amigos, como uno de los 12 voluntarios estadounidenses que participan en un programa de Wheels For The World, para instalar y distribuir 200+ sillas de ruedas a jóvenes y adultos, que de otro modo no experimentarían movilidad.El invitado de esta semana es Leonardo Céspedes de Bayamo, Cuba, un predicador bautista y padre de dos hijos, incluyendo un hijo con discapacidades intelectuales y físicas.   Leonardo y su esposa, Mairelis, han estado casados durante 26 años y son los orgullosos padres de dos hijos; su hija Reveca (23), que es profesora, y su hijo Marko (20), que tiene discapacidades intelectuales no diagnosticadas, sufre convulsiones y tiene problemas de audición.  Marko fue uno de los destinatarios de una silla de ruedas.Durante su visita, David habló y grabó entrevistas con dos cubanos conectados con la comunidad de discapacitados en Cuba.  Un agradecimiento especial a Dairy Hernández, la joven cubana que sirvió como una de las traductoras de David durante la semana y por su ayuda para traducir el episodio de hoy en inglés y español.  Eso es todo en este episodio del podcast Dad to Dad de SFN.  Mostrar Notas - WhatsApp - 53 58 01 426 627Correo electrónico - Correo electrónico - leobayamo@nauta.cuJoni y sus amigos - https://joniandfriends.org/ACLIFIM (Asociación Cubana de Personas con Discapacidad Física - Motora - https://www.aclifim.cu/Red de Padres Especiales - SFN es un programa de tutoría de padre a padre para padres que crían niños con necesidades especiales. Muchos de los 700+ Padres Mentores de SFN, que están criando niños con necesidades especiales, han dicho: "Ojalá hubiera algo así cuando recibimos por primera vez el diagnóstico de nuestro hijo. Me sentí tan aislada.  No había nadie dentro de mi familia, en el trabajo, en la iglesia o dentro de mi grupo de amigos que entendiera o pudiera relacionarse con lo que estaba pasando".Los padres mentores de SFN comparten sus experiencias con los padres más jóvenes más cerca del comienzo de su viaje criando a un niño con las mismas o similares necesidades especiales. Los Padres Mentores de SFN NO ofrecen asesoramiento legal o médico, eso es lo que hacen los abogados y los médicos. Simplemente comparten sus experiencias y cómo han aprovechado al máximo las situaciones difíciles.Echa un vistazo al canal de YouTube de 21CD con docenas de videos sobre temas relevantes para los padres que crían niños con necesidades especiales: https://www.youtube.com/channel/UCzDFCvQimWNEb158ll6Q4cA/videos Por favor, apoye a la SFN. Haga clic aquí para donar: https://21stcenturydads.org/donate/Red Especial de Padres: https://21stcenturydads.org/Grupo de Mentes Maestras de Papás de SFN - https://21stcenturydads.org/sfn-mastermind-group/Obtenga más información sobre Horizon Therapeutics: la ciencia y la compasión trabajan juntas para transformar vidas. https://www.horizontherapeutics.com/

This month as part of our Carrier Connections program, we are discussing navigating romantic relationships as a female impacted by X-linked disease. In this episode, Remember The Girls founder, Taylor Kane, brings on her partner of 5 years to discuss how Taylor being a carrier of ALD has impacted their relationship. Carrier Connections is sponsored by Horizon Therapeutics, Sanofi, and Ultragenyx Pharmaceutical. For more information about our organization, check out ⁠⁠⁠⁠⁠⁠rememberthegirls.org⁠⁠⁠⁠⁠⁠.

Our Carrier Connections program features a different X-linked condition each month with the goal to increase awareness of X-linked conditions and how they impact the lives of women and girls. This month, we are featuring Lesch-Nyhan syndrome (LNS). LNS is an X-linked disorder caused by a mutation in the gene, HPRT1, which plays a critical role in the body's ability to process purines. With the recycling of purines involved in the production of uric acid, this deficiency or complete lack of function in the HPRT1 gene in individuals with LNS results in excess amounts of uric acid in the body. This buildup of uric acid has many toxic effects on the body, contributing to a variety of neurological and behavioral issues. Perhaps most notably, individuals with LNS suffer from self-mutilative behaviors that tend to manifest around the age of two or three. Today, we are bringing on Gaby Ponce. Gaby Ponce is from Mexico and mother to Antonio, who has Lesch-Nyhan syndrome. She is the director of the Fundación Amor y Fuerz Lesch Nyhan. The foundation supports 11 families here in Mexico and helps them access medication, rehab therapy online, checkups every six months with a nephrologist and neurologist, dental extraction surgeries, wheelchairs, and more. They work with Love Never Sinks in the United States and Lesch Nyhan Action in France to advocate for a gene therapy treatment. Carrier Connections is sponsored by Horizon Therapeutics, Sanofi, and Ultragenyx Pharmaceutical. For more information about our organization, check out ⁠⁠⁠⁠⁠rememberthegirls.org⁠⁠⁠⁠⁠.

Our Carrier Connections program features a different X-linked condition each month with the goal to increase awareness of X-linked conditions and how they impact the lives of women and girls. This month, we are featuring Lesch-Nyhan syndrome (LNS). LNS is an X-linked disorder caused by a mutation in the gene, HPRT1, which plays a critical role in the body's ability to process purines. With the recycling of purines involved in the production of uric acid, this deficiency or complete lack of function in the HPRT1 gene in individuals with LNS results in excess amounts of uric acid in the body. This buildup of uric acid has many toxic effects on the body, contributing to a variety of neurological and behavioral issues. Perhaps most notably, individuals with LNS suffer from self-mutilative behaviors that tend to manifest around the age of two or three. Today, we are bringing on Michelle Lucas. Michelle Lucas is a 51-year-old carrier of LNS. She has been married for 26 years (27 on the 25th of this month) and has two sons with LNS, who passed away in 2010 (Daniel, age 14 & Keith, age 20). She loves to spend time with her husband and their two Saint Bernard's. She founded the nonprofit organization Love Never Sinks and served as the CEO from 2013-2021. She continues to advocate for others with LNS, trying to bring awareness, togetherness, and hopefully one day, a treatment. Carrier Connections is sponsored by Horizon Therapeutics, Sanofi, and Ultragenyx Pharmaceutical. For more information about our organization, check out ⁠⁠⁠⁠rememberthegirls.org⁠⁠⁠⁠.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. A new report says more than 50 Chicago businesses have expanded or relocated to Ireland. Abbott Labs, Horizon Therapeutics, Aon, and Illinois Tool Works are among the companies with an expanding presence in Ireland. The Chicago Tribune reports nearly 1,000 U.S. […]

This 15-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-pathophysiology/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 30-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-treatment-options/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org Copyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 45-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

**This conversation includes the topics of suicidal and self-harm ideation. We understand that not everyone is capable of hearing such conversations. Viewer discretion is advised.** This episode of the IDF Podcast is presented with support from Takeda, Horizon Therapeutics, CSL Behring, and Grifols. On this episode of The IDF Podcast, we turned to six young people who are longtime volunteers, Cassie Mummert, Darcy Gott, Ethan McGrew, Jesse McCall, Lance McCall, and Victoria Medl to discuss how they navigate the stress of college, postgraduate studies, and mental wellness with primary immunodeficiency. The information, terminology, and opinions presented in this forum do not necessarily reflect the views of IDF, its Board of Trustees, sponsors, or donors.

Each month, our Carrier Connections program features a different X-linked condition with the goal to increase awareness and education of X-linked conditions and how they impact females. This month, we are featuring X-linked ichthyosis (XLI). XLI is a rare X-linked condition caused by a deficiency in the enzyme steroid sulfatase which, under normal conditions, functions to maintain the integrity of the skin. In individuals with X-linked ichthyosis, this protein's normal function is interrupted, causing cholesterol to accumulate and the shedding of dead skin cells to be prevented. Previous work into the condition, led by Dr. William Davies and colleagues, has shown that individuals with XLI are substantially more likely than non-affected individuals to present with developmental disorders, such as Attention Deficit Hyperactivity Disorder (ADHD) and autism. Today, we are joined by Dr. William Davies! Dr. Davies is interested in the (epi)genetic mechanisms underlying sex differences in brain function and behavior. His work focusses on the role of genes on the sex chromosomes (i.e. the X and Y), which are asymmetrically inherited between the sexes. A principal aim of his research is to elucidate why the sexes are differentially vulnerable to common and disabling disorders such as autism and ADHD, and ultimately to help develop more effective sex-specific therapies. Carrier Connections is sponsored by Horizon Therapeutics, Sanofi, and Ultragenyx Pharmaceutical. For more information about our organization, check out ⁠⁠⁠⁠rememberthegirls.org⁠⁠⁠⁠.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Our Carrier Connections program features a different X-linked condition each month with the goal to increase awareness of X-linked conditions and how they impact the lives of women and girls. This month, we are featuring Hunter syndrome. Hunter syndrome is an X-linked genetic disorder caused by the deficiency of the iduronate 2-sulfatase enzyme, an essential protein required for sugar breakdown. As a result, a specific type of sugar molecule, glycosaminoglycans (GAG), builds up in the cell, causing widespread issues in the physical and mental development of individuals affected by this syndrome. Today, we are bringing on Cristol O'Loughlin, founder & CEO of ANGEL AID CARES and a carrier of Hunter syndrome. Cristol is fiercely passionate about providing social, emotional, physical and financial relief to Raregivers™ ~ patients, caregivers, and professionals who hold both hope and grief in the same human heart. Carrier Connections is sponsored by Horizon Therapeutics, Sanofi, and Ultragenyx Pharmaceutical. For more information about our organization, check out ⁠⁠⁠rememberthegirls.org⁠⁠⁠.

In this video, we'll perform an AMGN stock analysis and figure out what Amgen looks like based on the numbers. We'll also try to figure out what a reasonable fair value is for Amgen Inc. And answer is Amgen one of the best dividend stocks to buy at the current price? Learn about Amgen's acquisition of Horizon Therapeutics! Find out in the video above! Global Value's Amgen Inc. stock analysis. TIKR is the website I use for financial data in my videos. Join me and thousands of investors worldwide by using TIKR in your investment analysis. All funds from referrals directly support the channel to improve video quality! Referral link - https://www.tikr.com/globalvalue Check out Seeking Alpha Premium and score an exclusive $50 off coupon plus a free 7 day trial! All funds from affiliate referrals go directly towards supporting the channel! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ If you'd like to try Sharesight, please use my referral link to support the channel! https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) Discover new investing resources and directly support the channel by shopping my Amazon storefront! All commissions are reinvested to improve the quality of videos! https://www.amazon.com/shop/globalvalue Amgen Inc. ($AMGN) | Amgen Inc. Stock Value Analysis | Amgen Inc. Stock Dividend Analysis | AMGN Dividend Analysis | $AMGN Dividend Analysis | Amgen Inc. Intrinsic Value | AMGN Intrinsic Value | $AMGN Intrinsic Value | Amgen Intrinsic Value | Amgen Inc. Discounted Cash Flow Model | Amgen Inc. DCF Analysis | AMGN Discounted Cash Flow Analysis | AMGN DCF Model #AMGN #AMGEN #amgenstock #amgnstock #stockmarket #dividend #stocks #investing #valueinvesting #dividendstocks #dividendgrowthinvesting (Recorded October 30, 2023)

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über die plötzliche Champagnerlaune an den Märkten, die Kurshausse bei ProSiebenSat.1 und die abrupte Dollar-Schwäche beim MSCI World. Außerdem geht es um iShares Global Clean Energy (WKN: A0MW0M), Invesco Solar ETF (WKN: A2QQ9R), iShares Core MSCI World (WKN: A0RPWH), Invesco EQQQ Nasdaq-100 (WKN:A2N6RV), ARK Innovation (WKN: A14Y8H), iShares MSCI Global Semiconductors ETF (WKN: A3CVRA). Delivery Hero, Apple, Alphabet, Home Depot, CRH, Berkshire Hathaway, Linde, Eli Lilly, International Flavor & Fragrance, VWWare, Vertiv Holdings, Suncor Energy, Meta, Exxon Mobil, Uranium Energy, Nu Holdings, Helix Energy Solution, TSMC, Avis, Visa, Oracle, Boeing, Canadian National Railway, Thermo Fisher, Block, Fortinet, Booking Holdings, Splunk, Cisco Systems, Microsoft, Horizon Therapeutics, Abcam, Novo Nordisk. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Deals, mergers, partnerships, and acquisitions are key mechanisms as health organizations look to enter new markets, differentiate their value proposition, and achieve growth strategies. Despite a less than favorable economic environment, the health industry has seen some major headlines in this space this year. Jen and Mindy are joined by Vynamic's Deal Activation & Partnership Enablement Service Leads, Sean Martin and Kevin Fletcher, to discuss what's driving these deals and what health industry leaders should be thinking about to maximize their value.For more information about the work discussed in this episode, visit https://vynamic.com/what-we-do/services/deal-activation-partnership-enablement/ Podcast Tags: healthcare, healthcare news, mergers, acquisitions, deal activation, partnerships, health services, payers, providers, life sciences Source Links:Optimistic outlook for deals through 2023 M&A and venture trends in life sciences in 2023 A Look at Q2 M&A and Beyond: Are Conditions Ripe for a Strong 2024 M&A Rebound? The Kaiser Permanente-Geisinger deal: Questions and answers CVS closed $8B deal for health services company Signify Health Pfizer buys Seagen for $43B, boosts access to cancer drugs Amgen completes $27.8 billion Horizon Therapeutics deal Panel – Sean Martin, Kevin Fletcher, Mindy McGrath, Jen BurkeResearch & Production – Adrea Cope, Jen BurkeRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

How can patients help shape the future of scientific innovation? What's the vital role of the patient's voice in developing life-changing medicines? In this captivating episode, fresh off her thought-provoking appearance at the 9th Annual BioHealth Capital Region Forum, Dr. Theresa Podrebarac takes us on a journey through the dynamic landscape of autoimmune medicine. Dr. Podrebarac is a renowned physician scientist with a wealth of expertise in the biotech industry. As the Senior Vice President of Clinical Development at Horizon Therapeutics, she's at the forefront of bringing hope to patients with rare, autoimmune, and severe inflammatory diseases. Join us as we explore pivotal questions: What is Horizon Therapeutics' mission, and what are Dr. Podrebarac's primary responsibilities in this quest for life-changing medicines? How has Dr. Podrebarac's background as a rheumatologist influenced her belief in the importance of the patient's perspective in drug development? Discover Horizon's impressive journey in clinical development, with a sharp focus on autoimmune diseases. Dive into Horizon's global presence and the crucial role of its Maryland operations. What are the clinical goals that will shape the future of autoimmune medicine? Don't miss this enlightening conversation that delves into the nexus of science, patient advocacy, and innovation. Tune in now and become part of the future where patients' voices are not just heard but lead the way in shaping a brighter tomorrow. Available on all major podcasting platforms. Theresa Podrebarac, M.D., M.Sc., is a physician scientist with extensive development expertise in the biotech industry. At Horizon Therapeutics, Dr. Podrebarac leads the clinical development function dedicated to bringing medicines for rare, autoimmune and severe inflammatory diseases to patients. Prior to Horizon, Dr. Podrebarac served as chief medical officer at two biotech companies focusing on rare diseases.  She was also vice president, immunology clinical development at AbbVie where she helped develop approved therapies for psoriasis and rheumatoid arthritis. At Biogen, she championed the development of tools and techniques for early clinical proof of concept in diseases including scleroderma and lupus skin disease. Dr. Podrebarac holds a master of science in immunology from the University of Ottawa and a medical doctorate degree from Western University. She completed a postdoctoral fellowship in immunology at Harvard University.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today's episode covers a range of updates in the industry.First, we turn our attention to the commercial hurdles facing RSV vaccines. Public health officials and drugmakers are working to raise awareness of RSV among older adults at risk. They are also encouraging them to get an additional respiratory shot alongside those for COVID-19 and flu. This rollout poses a test for the industry.In a recent House hearing, the pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA traded blame over problems in the prescription supply chain. They discussed the high costs of drugs and the role that PBMs play in driving up prices. This ongoing debate highlights the challenges within the industry.Moving on, Alvotech has received a new FDA review for its biosimilar of Humira. The regulator had previously rejected Alvotech's copycat drug due to manufacturing issues with a plant in Europe. This new review brings hope for Alvotech's biosimilar.Novartis has canceled its partnership with Beigene as its cancer drug gains EU approval. This decision leaves Novartis without a PD-1 inhibitor, marking a significant development for the company.Orchard is nearing an FDA decision on its rare disease gene therapy, Libmeldy. Three years after gaining European approval, Libmeldy is now under review in the US. This therapy has the potential to make a difference in the lives of patients.Shifting gears, an FDA panel has backed Alnylam's drug Onpattro for cardiomyopathy of ATTR amyloidosis, despite doubts over its benefit. This endorsement provides support for this drug's use in treating this condition.We also have various resources for further reading and upcoming events available. Check out Biopharma Dive and its publications for more information.In another news story, Roche's Genentech has partnered with PeptiDream to develop targeted radioisotopes for certain cancers. This collaboration expands their efforts in radiopharmaceuticals and shows promise for future treatments.Taysha has made the decision to drop its lead gene therapy, TSHA-120, following feedback from the FDA. The agency proposed additional studies that Taysha determined would be too challenging to pursue. Additionally, Taysha's partner, Astellas, has declined to pick up an option for the therapy. These developments mark a setback for Taysha.The FDA has also rejected ARS Pharmaceuticals' Neffy as a nasal spray for allergic reactions. Despite receiving backing from the Pulmonary-Allergy Drugs Advisory Committee, this rejection is a setback for ARS. The nasal spray was seen as an alternative to the EpiPen for severe allergic reactions.In other news, Genentech and PeptiDream have signed a potential $1 billion deal for the development of macrocyclic peptide-radioisotope drug conjugates. This partnership has the potential to advance cancer treatments and improve patient outcomes.Recode Therapeutics has raised $260 million in a series B financing round to advance its mRNA therapies. This funding will support further development in this promising field.The clearance of the Amgen-Horizon merger has been seen as a setback to the FTC's antitrust enforcement plans. The consent agreement between Amgen, Horizon Therapeutics, and the FTC could have significant implications for future merger and acquisition challenges.Lastly, Verisim Life has released an ebook on how artificial intelligence can transform R&D with early-stage translational insights in model-informed drug development. This resource provides valuable information on the potential of AI in drug development.That's all for today's episode. Thank you for tuning in to Pharma and Biotech Daily. Stay informed and stay ahead in the industry.

Horizon Therapeutics' Geoff Curtis has a wide range of responsibilities, including corporate affairs, strategy, audience engagement and innovation while overseeing more than 50 staffers in corporate comms, brand, government affairs, corporate social responsibility and more.And he built it all from a team of one person. Curtis talks about that process on the latest edition of The PR Week, as well as strategies for mentorship, the importance of internal communications and much more. Plus, cohost and PRWeek senior reporter Jess Ruderman talks about the biggest marketing and communications news of the week, including the 2023 edition of PRWeek's Hall of Fame, acquisitions by ICR and Omnicom PR Group and new roles for Stacey Jones and Brandee Barker. Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek

Constructing deal terms to take advantage of both the translational research benefits in China and the market opportunity in the U.S. is slowly emerging as a strategy to advance CAR T cell innovation. On the latest BioCentury This Week podcast, BioCentury's editors discuss how deals for the technology have evolved since the 2017 partnership between Legend and Janssen for Carvykti and the opportunity for East-West collaborations to drive CAR T cell development.BioCentury's editors also assess why the FTC made a deal with Amgen that will allow the company's $27.8 billion acquisition of Horizon Therapeutics to proceed, and how an agreement by Regeneron on international pricing of a COVID-19 mAb could clear the path to confirmation of Monica Bertagnolli as the next NIH director.

Pink Sheet reporter and editors discuss the US Federal Trade Commission ending its attempt to block the Amgen acquisition of Horizon Therapeutics (:28), a proposed public-private partnership to develop ultra-rare cancer drugs (9:54), and a slow-down in ANDA submissions to the US Food and Drug Administration (22:02). More On These Topics From The Pink Sheet FTC's Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement: https://pink.citeline.com/PS148804/FTCs-Test-Case-Opposing-Amgen-Horizon-Deal-Ends-With-No-Bundling-Agreement Ultra-Rare Tumors: Public-Private Partnership Eyed To Boost Drug Development: https://pink.citeline.com/PS148813/Ultra-Rare-Tumors-Public-Private-Partnership-Eyed-To-Boost-Drug-Development ANDA Submissions Lagging As FY 2023 Nears Its End: https://pink.citeline.com/PS148818/ANDA-Submissions-Lagging-As-FY-2023-Nears-Its-End

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. The Federal Trade Commission (FTC) has allowed Amgen's $28 billion acquisition of Horizon to proceed, with conditions. This settlement may ease concerns about regulatory hurdles for future deals in the industry. However, FDA documents suggest that Sage's depression drug, zurzuvae, may face challenges in obtaining broad approval due to concerns about side effects. On a positive note, Roche has claimed success in a study for its targeted lung cancer drug, Alecensa, with unprecedented results. This could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.In terms of investment, Julie Yoo from venture capital firm Andreessen Horowitz believes that the healthcare industry is at an inflection point and compared it to the internet era of 1999. Biotech mergers and acquisitions (M&A) activity is also picking up again, with Amgen's acquisition of Horizon set to become the largest industry deal since AstraZeneca's buyout of Alexion. Drug pricing in the US is also a trending topic, with launch prices steadily rising in certain therapeutic areas like cancer.Moving on to policy news, the Biden administration has proposed new nursing home staffing minimums to improve the quality of care in these facilities. Walgreens CEO Roz Brewer is stepping down and will be replaced by an executive with "deep healthcare experience." Amir Dan Rubin, CEO of One Medical, is also resigning from his position. The Office of the National Coordinator for Health Information Technology has chosen the Sequoia Project to oversee the Trusted Exchange Framework and Common Agreement (TEFCA) once again.In other updates, Roz Brewer's sudden departure from Walgreens has left many wondering about the reason behind it. Psycheceutical is developing a topical delivery technology for ketamine, which could have broader implications for other drugs. Ketamine has shown promise in treating mental health conditions such as treatment-resistant depression. J&J's Spravato, an FDA-approved drug for treatment-resistant depression, is administered nasally, but clinicians believe that intravenous ketamine is more effective. Psycheceutical aims to explore the potential relief provided by applying ketamine topically on the back of the neck.The rare disease market has seen significant growth in recent years, with pharmaceutical companies exploring treatments for these conditions. Ketamine's effectiveness in battling mental health conditions is being recognized, shifting its perception from a party drug to a potential therapeutic option. The text also mentions upcoming events and recent articles on various topics.In regulatory news, the FTC has given clearance for Amgen's acquisition of Horizon Therapeutics, subject to certain restrictions. Alvotech has resubmitted a Biologics License Application (BLA) to the FDA seeking an interchangeable designation for its biosimilar of Humira. Lawmakers have called on Lilly, Novo Nordisk, and Sanofi to provide details on their insulin assistance programs. Alkermes has settled a patent lawsuit with Teva over the generic version of Vivitrol. Biontech and DualityBio are moving their antibody-drug conjugate (ADC) into Phase III trials for HER2-low breast cancer.Lastly, Bayer has reported positive early data for a Parkinson's cell therapy treatment it acquired in 2019. Epigenic, a Chinese startup, has raised funds to use CRISPR tools to edit the epigenome and alter gene expression without changing DNA. Catalent, a contract development and manufacturing organization (CDMO), is expanding its board and setting up a committee to review its business and capital allocation priorities. Several biotech companies have made advancements in constructing small-molecule drugs to target RNA, revolutionizing the industry.These developments highlight significant activities in the p

P.M. Edition for Sept. 1. The August jobs report shows a continued slowdown in hiring this summer, as the Federal Reserve looks to cool the labor market. Gwynn Guilford reports. Plus, the Federal Trade Commission drops its legal challenge to Amgen's $27.8 billion deal to buy Horizon Therapeutics. Financial enforcement reporter Dave Michaels has the details. And, are some Washington politicians too old to hold the job? White House reporter Annie Linskey has more on what voters think. Annmarie Fertoli hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla and David Faber kicked off a new market week after a Friday in which the Dow posted its best day in about three weeks and Fed Chair Powell delivered his Jackson Hole speech. What should investors make of Nvidia erasing last week's gains from its blowout quarter? Also in focus: Commerce Secretary Raimondo's visit to China and that country's moves to boost its capital markets, 3M shares up sharply on reports the company is near a $5.5 billion settlement related to its earplugs, the FTC pauses its challenge to Amgen's $27 billion deal to acquire Horizon Therapeutics. Squawk on the Street Disclaimer

Scott Wapner and the investment committee discuss the final days of a rocky month for stocks and what the famously fragile fall will hold for your money. The chart of the day is on Disney. The call of the day is a downgrade for CrowdStrike ahead of earnings. And the panel talks biotech as shares of Horizon Therapeutics pop.Investment Committee Disclosures 

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über Notenbanker, die Hoffnung wecken, neue Sorgen bei Vonovia und eine Wachstumsregion mit Renditechancen. Außerdem geht es um Nucera, Fortescue Metals Group, Amgen, Horizon Therapeutics, Ezz Steel, Riyadh Cables Group, Middle East Healthcare Company, MSCI GCC Select Swap (WKN: A12B98), iShares MSCI Saudi Arabia Capped ETF (WKN: A14ZV2), Franklin MENA Fund (WKN: A0Q0A0), iShares Core MSCI World (WKN: A0RPWH), Xtrackers MSCI World UCITS ETF (WKN: A1XB5U), Amundi MSCI World UCITS ETF (WKN: A2H59Q), Invesco MSCI World UCITS ETF (WKN: A0RGCS), PDD Holding, Amazon. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.Activity OverviewThis PER® Spectives™ podcast features a discussion among 3 optometrists on challenges and unmet needs associated with traditional treatments for meibomian gland dysfunction (MGD)-related dry eye disease (DED) — and opportunities for MGD treatment that may come with new and emerging topical therapies. In addition, the panel discusses myths and misconceptions that may affect outcomes in patients with MGD-DED. This program is designed to help clinicians better appreciate the impact ofMGD-DED on patients and optimize the growing toolkit of available therapies.Accreditation/Credit DesignationPhysicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Bausch + Lomb.Target Audience This educational activity will be targeted to practitioners who are involved in treating patients with MGD, such as Optometrists, Ophthalmologists, NPs, PAs, and nurses.Learning ObjectivesUpon successful completion of this activity, you should be better prepared to: • Analyze key trial data and real-world evidence surrounding current treatments for MGD-associatedDED• Evaluate key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DEDFaculty:Mile Brujic, OD, FAAOPartnerPremier Vision GroupBowling Green, OHDisclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, WalmanOptical, ZeaVisionDavid Kading, OD, FAAO, FCLSADisclosuresWalter Whitley, OD, MBA, FAAODirector of Professional Relations and EducationRegional Medical Director - Mid-AtlanticEyeCare Partners, LLCDisclosures: Consultant: Alcon, Allergan, Bausch + Lomb, Bruder, I-MED Pharma USA, KalaPharmaceuticals, Novartis, Oyster Point Pharma, Regener-Eyes, Santen Pharmaceutical, ScienceBasedHealth, Sun Pharma, Tarsus Pharmaceuticals, Théa Pharma; Speakers' Bureau: Alcon, Allergan, Bausch +Lomb, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, Santen Pharmaceutical, ScienceBasedHealth, Sun Pharma.The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs.Learners are advised to consult prescribing information for any products discussed. Theinformation provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support

While Horizon Therapeutics has made plenty of waves in the biotech news cycle of late. While perhaps not as flashy as a perilous multibillion dollar acquisition deal or potential blockbuster readout, its formal establishment of a research team – comparatively pragmatic as that may be – could have long-term consequences that are just impactful. On this week's episode of the Business of Biotech, we dig into why the company chose to establish a research function, learn why it chose Dr. Robert Stoffel, Ph.D. to run it, and get a step-by-step explainer on how Stoffel went about establishing the department, setting its goals and strategy, staffing it, and integrating it across teams at the fast-rising biopharmaceutical company. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.Activity OverviewThis PER® Spectives™ podcast features a discussion among 3 optometrists on concerns related to the use of preserved eye lubricants for patients with dry dye disease. In addition, the panel discusses developments in components within these products to support the ocular surface, including trehalose and hyaluronic acid. This program is designed to help clinicians better match specific eye lubrication products to individual patient needs, thereby improving the chances of superior outcomes.Accreditation/Credit DesignationPhysicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Thea Pharmaceuticals, Inc.Target Audience  This educational activity will be targeted to clinicians who are involved in treating patients with dry eye disease such as optometrists, ophthalmologists, NPs, PAs, and nurses.Learning ObjectivesUpon successful completion of this activity, you should be better prepared to: • Recognize the potential deleterious impact preservatives have on the ocular surface• Summarize novel formulations for the management of DEDFaculty:Mile Brujic, OD, FAAOPartnerPremier Vision GroupBowling Green, OHDisclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, WalmanOptical, ZeaVisionDavid Kading, OD, FAAO, FCLSACEO/OwnerSpecialty EyeKirkland, WA / Bellevue,WADisclosures:Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, CooperVision, EyeVance, Eye Promise Euclid, Horizon Lumenis, Oculus,Orasis, Oculaphire, Medmont, Novartis, Sun Pharma, TearScience, Thea, Trukara, Valley Contax, Visus Theraputics, Zeiss, andZeaVision.DisclosuresSelina R. McGee, OD, FAAOCEO/OwnerBeSpoke VisionPresidentIntrepid Eye SocietyOklahoma Board of Examiners in OptometryEdmond, OKDisclosures: Consultant: Horizon Therapeutics.The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs.Learners are advised to consult prescribing information for any products discussed. Theinformation provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial supportfor this activity.

During Graves' Disease Awareness Month this July, hear from Donna Moss - mother, wife, grandmother, interior designer, and HGTV star - about her experience with Graves' disease and her two-year journey to receiving a diagnosis. Donna will also discuss how she took her health into her own hands after noticing symptoms of Thyroid Eye Disease (TED). Donna also reminds listeners it's not too late to learn about TED, monitor for symptoms, and seek care from a TED Eye Specialist. To learn more, visit www.FOCUSonTED.com and join the Listen To Your Eyes Facebook, Instagram and YouTube communities. ©2023 Horizon Therapeutics plc DA-UNBR-US-01723 07/23

It's time to welcome back Chris DeMuth for his monthly state of the markets. For this May 2023 edition, Chris shares his thoughts on the government suing to block the Horizon Therapeutics sale to Amgen, government's history of antitrust cases, Amazon / iRobot deal, evaluating judges in antitrust cases, banking sector and more! For more information about Rangeley Capital, please visit: http://www.rangeleycapital.com/ Chapters: [0:00] Introduction + Episode sponsor: Stream by Alphasense [1:58] What's on Chris' mind for May 2023 starting with government suing to block the Horizon Therapeutics sale to Amgen and government history of antitrust cases [9:22] Amazon / iRobot deal [13:23] What is the government arguing in the Amgen / Horizon case [16:39] Evaluating antitrust cases, judges in particular + Amgen / Horizon case cont'd [29:09] Banking sector: update on regional banks and how Chris thinks about the space right now [39:15] Closing thoughts Today's episode is sponsored by: Stream by Alphasense Are traditional expert calls in the investment world becoming obsolete? According to Stream, they are, and you can access primary research easily and efficiently through their platform. With Stream, you'll have the right insights at your fingertips to make the best investment decisions. They offer a vast library of over 26,000 expert transcripts, powered by AI search technology. Plus, they provide competitive rates on expert call services, and you can even have an experienced buy-side analyst conduct the calls for you. But that's not all. Stream also provides the ability to engage with experts 1-on-1 and get your calls transcribed free-of-charge—all for 40% less than you would pay for 20 calls in a traditional expert network model. So, if you're looking to optimize your research process and increase ROI on investment research spend, Stream has the solution for you. Head over to their website at streamrg.com to learn more. Thanks for listening, and we'll catch you next time. For more information: https://www.streamrg.com/

(0:00) Bestie intros!: Reddit Performance Reviews (5:14) Quick AIS 2023 update (6:27) AI Senate hearing: Sam Altman playing chess with regulators, open-source viability (21:25) Regulatory capture angle, "preemptive regulation," how AI relates to nuclear, insider insights from the White House's AI summit (43:33) Elon hires new Twitter CEO (48:46) Lina Khan moves to block Amgen's $27.8B acquisition of Horizon Therapeutics (1:02:30) Apple's AR goggles are reportedly being unveiled at WWDC in early June, platform shift potential, how it deviates from Apple's prior launch strategies (1:07:45) Residential and commercial real estate headwinds (1:15:29) Unrest in SF and NYC after two recent tragic incidents ended in death (1:24:20) Soros political motivations for backing progressive DAs Follow the besties: https://twitter.com/chamath https://linktr.ee/calacanis https://twitter.com/DavidSacks https://twitter.com/friedberg Follow the pod: https://twitter.com/theallinpod https://linktr.ee/allinpodcast Intro Music Credit: https://rb.gy/tppkzl https://twitter.com/yung_spielburg Intro Video Credit: https://twitter.com/TheZachEffect Referenced in the show: https://techcrunch.com/2023/05/18/psst-gary-marcus-is-happy-to-help-regulate-ai-on-behalf-of-the-u-s-government/ https://twitter.com/chamath/status/1658913074106236931 https://www.mosaicml.com/blog/mpt-7b https://huggingface.co/spaces/HuggingFaceH4/open_llm_leaderboard https://artificialintelligenceact.eu https://futurism.com/the-byte/warren-buffett-ai-atom-bomb https://www.cnbc.com/2023/05/12/nbcuniversal-ad-chief-yaccarino-resigns-as-sources-say-shes-in-talks-to-be-twitter-ceo.html https://www.wsj.com/articles/ftc-poised-to-block-amgens-27-8-billion-deal-for-horizon-therapeutics-a9c1b499 https://www.ftc.gov/system/files/ftc_gov/pdf/2310037amgenhorizoncomplainttropi.pdf https://www.benefitspro.com/2023/05/12/pbms-the-brokers-who-control-drug-prices-finally-get-washingtons-attention https://sharegpt.com/c/O6OKM9D https://www.wsj.com/articles/apple-mixed-reality-headset-9213ac1b https://twitter.com/PalmerLuckey/status/1657828947877560323 https://twitter.com/DavidSacks/status/1658955195450286081 https://www.foxnews.com/us/witness-jordan-neely-chokehold-death-calls-daniel-penny-hero https://www.reddit.com/r/nyc/comments/1njfls/try_to_stay_away_from_the_michael_jackson https://en.wikipedia.org/wiki/1984_New_York_City_Subway_shooting https://en.wikipedia.org/wiki/Guardian_Angels https://www.messynessychic.com/2019/03/26/in-the-shadows-with-nycs-self-styled-guardian-angels https://www.eviemagazine.com/post/media-falsely-representing-jordan-neely-10-year-old-photos-crucial-information https://twitter.com/Jason/status/1655716240500080640 https://www.foxnews.com/politics/george-soros-son-visited-white-house-dozen-times-since-biden-took-office-records-show

Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug industry. We also discuss the latest on Sarepta Therapeutics and its gene therapy for Duchenne muscular dystrophy, a turnaround story in the making at the Belgian drug maker Galapagos, and the effort to secure approval for a maternal RSV vaccine.

The Federal Trade Commission sued to block the biotechnology company Amgen's $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said it repelled an unprecedented barrage of Russian missiles over Kyiv. Mentioned in this podcast:FTC warns of ‘rampant' pharma consolidation as it targets $28bn Amgen dealItaly overhauls plans for €200bn in EU Covid recovery fundsUkraine says it repelled ‘exceptional' barrage of Russian missilesThe FT News Briefing is produced by Fiona Symon, Sonja Hutson and Marc Filippino. The show's editor is Jess Smith. Additional help by Katie McMurran, Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Topher Forhecz is the FT's executive producer. The FT's global head of audio is Cheryl Brumley. The show's theme song is by Metaphor Music. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Carl Quintanilla Jim Cramer and David Faber discussed what Elon Musk told David in a wide-ranging CNBC exclusive interview -- including the future for both Tesla and Twitter. Hear what Musk said about AI, the impact of his tweets, U.S-China tensions over Taiwan, plus why he passionately views work from home as a moral issue. The anchors also reacted to comments by House Speaker Kevin McCarthy about the debt ceiling talks. He told CNBC that he doesn't believe the U.S. will default. Also in focus: Target and TJX earnings, sources told David that Amgen is confident it will prevail over the FTC's push to block the company's $28 billion takeover of Horizon Therapeutics.  Squawk on the Street Disclaimer

Bloomberg Intelligence Senior Litigation Analyst, Jennifer Rie and Bloomberg Antitrust Reporter Leah Nylen discuss the latest with the FTC's suit to block Amgen's deal with Horizon Therapeutics. Mary Lou Gardner, Associate Partner for CPG, Retail and Logistics at Infosys Consulting discusses consumer outlook in retail. Bloomberg Businessweek Editor Joel Weber and Bloomberg Editorial Senior Commodities Reporter James Attwood discuss the green energy transition and Chile's copper problem. And we Drive to the Close with Hank Smith, CIO of Haverford Trust. Hosts: Carol Massar and Matt Miller. Producer: Sara LivezeySee omnystudio.com/listener for privacy information.

US equity futures are indicating a broadly flat open as of 05:00 ET. This follows mixed Asian trade, while European equity markets are lower. There is more optimism surrounding US debt ceiling negotiations with key players meeting again at the White House today. China activity data missed consensus, confirming a stuttering recovery.Companies Mentioned: Amgen, Horizon Therapeutics, Walt Disney, TSMC

In this Episode: How Kyle ended up at Cracker Barrell for chicken fried steak at lunchtime You Got This, Mental Health featuring Andra Stratton - Managing expectations for drug development Asking for help is complicated.  The Dudes talk through some of the different scenarios that make it so. Thank you notes - Gail Moore   We all need help sometimes.  However asking for, and receiving help are not straight forward.  Sometimes our pride gets in the way of other people trying to offer help.  Links and Resources: Asking for help is so damn hard.  Here's how to make it easier This episode brought to you in part by Horizon Therapeutics. In honor of Rare Disease Day, the #RAREis Global Advocate Grant program is awarding 50 grants totaling $250,000 to global patient advocacy organizations working to support the community. Learn more and apply at rareiscommunity.com/grant

In this Episode: Dr. Kyle gives his advice. You Got This, Mental Health - Self Image Audrey Greenberg is the CBO of Discovery Labs and the Center for Breakthrough Medicines.  She talks with The Dudes about how authenticity can benefit all of us. Thank you notes - Bill at Meineke & Taylor Wohler   When you come as you are, others feel free to bring their authentic selves to the conversation.  This is one of the many things we took away from our conversation with Audrey Greenberg, CBO of the Center for Breakthrough Medicines. Greenberg manages the 1.6 million-square-foot campus at the Discovery Labs King of Prussia, PA one of the largest facilities for life sciences and technology in the world. Links and Resources: Mental Health - Self Image This episode brought to you in part by Horizon Therapeutics. In honor of Rare Disease Day, the #RAREis Global Advocate Grant program is awarding 50 grants totaling $250,000 to global patient advocacy organizations working to support the community. Learn more and apply at rareiscommunity.com/grant

In this Episode: Almost a year later, Kyle gives an update on his wheelchair drama. You Got This, Mental Health featuring Andra Stratton - Managing our expectations for Drug Development. The Dateability App - Designed by someone with a disability for the disabled community. Thank you notes - Dr. Anna Stepanova & Aaron Fisher   After learning of her own disability and chronic illness, Jacqueline was exposed to a persistent ableist mentality and she wasn't a fan. This showed up a lot in her dating life and she couldn't find a dating app that she felt safe using and that helped her meet people that understood disability. So, she teamed up with her sister and they launched The Dateability App. Links and Resources: Mental Health Uplifting Athletes This episode brought to you in part by Horizon Therapeutics. In honor of Rare Disease Day, the #RAREis Global Advocate Grant program is awarding 50 grants totaling $250,000 to global patient advocacy organizations working to support the community. Learn more and apply at rareiscommunity.com/grant

Welcome to Season 9! Dolly Parton wants to see more kindness in 2023. However if you ask Sean, kindness is not the issue - it's awareness of others around you. It will make sense after you listen. Sean's column on the subject: No Good Excuse This episode brought to you in part by Horizon Therapeutics. In honor of Rare Disease Day, the #RAREis Global Advocate Grant program is awarding 50 grants totaling $250,000 to global patient advocacy organizations working to support the community. Learn more and apply at rareiscommunity.com/grant

Today, Dee and Anand discuss Anand's Sunday take, Elon's Chappelle appearance, S&P 500's response to the CPI report, SBF's arrest, SBA's PPP fraud estimates, used cars' prices, Moderna's mRNA cancer vaccine, and TikTok's possible demise. Timeline of What Was Discussed: Is Anand a liberal snowflake? (1:36)  Boos or cheers? (11:30)  Inflation is still pretty high. (21:14)  Scary news for private tech companies in the growth stage. (26:59)  SBF arrested! (36:27)  The PPP fraud. (41:48)  There is more pain coming to the used car markets. (46:38)  ‘Vaccine' needs to be rebranded. (50:32)  Is the TikTok ban in the U.S. happening?! (57:19)  Related Links/Products Mentioned  Elon Musk booed at Dave Chappelle show amid Twitter anger  Elon Musk is no longer the richest person in the world  U.S. Inflation Eased in November, CPI Report Shows  Stocks making the biggest moves midday: Horizon Therapeutics, Coupa Software, Weber and more  Sam Bankman-Fried criminal charges unsealed: Conspiracy to defraud the U.S., wire fraud, securities fraud, and money laundering  WTAF??  After the dust settled it was calculated that the PPP program saved a total of 2.3M jobs at a cost of $286k per job. - Levi on Twitter  Used car prices are down 3.3% from a year ago — but still 'grossly inflated,' auto expert says. Here's where to find deals  Moderna's mRNA Cancer Vaccine Shows Promise in Preliminary Study  Lawmakers unveil bipartisan bill that aims to ban TikTok in the U.S.  Connect with Group Chat! Watch The Pod #1 Newsletter In The World For The Gram Tweet With Us Exclusive Facebook Content We're @groupchatpod on Snapchat